Indeed, GLP-1 analogs, such as exenatide and liraglutide, already safely in clinical use to treat T2DM, have been extensively studied in clinical trials of neurodegenerative diseases. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.